Vivesto ABOASMY 26 Net Current Asset Value is $0.01 as of Mar. 2026, which is 100% below its 10-year median of 4.20. GuruFocus rates OASMY with a GF Score™ of 26/100. The stock has 1 warning sign investors should review. Among 613 Drug Manufacturers companies, Vivesto AB ranks better than 61.34% on this metric.
In calculating the Net Current Asset Value (NCAV), Benjamin Graham means a company's current assets (such as cash, marketable securities, and inventories) minus its total liabilities (including preferred stock, minority interest, and long-term debt).
Vivesto AB's net current asset value per share for the quarter that ended in Mar. 2026 was $0.01.
The historical rank and industry rank for Vivesto AB's Net Current Asset Value or its related term are showing as below:
During the past 13 years, the highest Price-to-Net-Current-Asset-Value Ratio of Vivesto AB was 14.09. The lowest was 1.47. And the median was 4.20.
OASMY's Price-to-Net-Current-Asset-Value is not ranked *
in the Drug Manufacturers industry.
Industry Median: 5.71 * Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
Vivesto AB (OTCPK:OASMY) Net Current Asset Value Explanation
Benjamin Graham first discussed net current asset value (NCAV) in the 1934 edition of "Security Analysis", which he coauthored with David Dodd. In the book, (net) current asset value is defined as:" current assets alone, minus all liabilities and claims ahead of the issue."
The common definition of NCAV is: NCAV = current assets – [total liabilities + minority interest + preferred stock]
Net current assets exclude not only the intangible assets but also the fixed and miscellaneous assets. In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. In "Security Analysis", preferred stock is dubbed "an imperfect creditorship position" that is best placed on the balance sheet alongside funded debt.
One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Grahams strategy produced similar results.
Benjamin Graham looked for companies whose market values were less than two-thirds of their Net-Net Working Capital. They are collected under our Net-Net screener.
Vivesto AB Net Current Asset Value Related Terms
Vivesto AB Net Current Asset Value Historical Data
* Premium members only.
The historical data trend for Vivesto AB's Net Current Asset Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
OASMY vs ZTS, UTHR, VTRS: Net Current Asset Value Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Vivesto AB's Price-to-Net-Current-Asset-Value, along with its competitors' market caps and Price-to-Net-Current-Asset-Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Vivesto AB Price-to-Net-Current-Asset-Value vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Vivesto AB's Price-to-Net-Current-Asset-Value distribution charts can be found below:
* The bar in red indicates where Vivesto AB's Price-to-Net-Current-Asset-Value falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Net Current Asset Value of $0.01 mean?
Vivesto AB (OASMY) has a Net Current Asset Value of $0.01 as of Mar. 2026. Ben Graham's net current asset value equals the per-share value of total current assets less total liabilities. View historical data on Vivesto AB and its competitors. This is 100% below median its historical median of 4.20. Over the past decade, Vivesto AB's Net Current Asset Value has ranged from 1.47 to 14.09. According to the industry distribution chart, Vivesto AB ranks #237 out of 613 companies in the Drug Manufacturers industry, placing it in the top 38.7%.
Is Vivesto AB's Net Current Asset Value too high?
Vivesto AB's current Net Current Asset Value of $0.01 is 100% below median its 10-year median of 4.20. Over the past 10 years, this metric has ranged from a low of 1.47 to a high of 14.09. The Drug Manufacturers industry median Net Current Asset Value is 5.71. Vivesto AB's value of $0.01 is 99.8% below this industry median. Based on the distribution chart, Vivesto AB ranks #237 out of 613 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Vivesto AB has a GF Score™ of 26/100, reflecting its overall financial health beyond just this single metric.
How does Vivesto AB's Net Current Asset Value compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Vivesto AB ranks #237 out of 613 companies for Net Current Asset Value. This puts Vivesto AB in the upper half of its industry. The industry median Net Current Asset Value is 5.71. Vivesto AB's value of $0.01 is 99.8% below this benchmark. Historically, Vivesto AB's own Net Current Asset Value has ranged from 1.47 to 14.09 over the past decade. While the company's 10-year median is 4.20 vs. the industry median of 5.71, Vivesto AB has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Current Asset Value for a Drug Manufacturers company?
The median Net Current Asset Value among Drug Manufacturers companies is 5.71, based on 613 companies in the industry. Companies in the top quartile (top 25%) have a Net Current Asset Value significantly above this median, while those in the bottom quartile fall well below. However, Net Current Asset Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Vivesto AB's current Net Current Asset Value of $0.01 is 99.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Current Asset Value mean?
A high Net Current Asset Value can signal that a stock is expensive relative to its fundamentals. Ben Graham's net current asset value equals the per-share value of total current assets less total liabilities. View historical data on Vivesto AB and its competitors. For the Drug Manufacturers industry, the median Net Current Asset Value is 5.71 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Vivesto AB's current Net Current Asset Value is $0.01, which is 100% below median its own 10-year median of 4.20. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vivesto AB stock overvalued right now?
Vivesto AB (OASMY) has a current Net Current Asset Value of $0.01. The current Net Current Asset Value is $0.01, which is 100% below median its 10-year median of 4.20 and 99.8% below the Drug Manufacturers industry median of 5.71. Vivesto AB's overall GF Score™ is 26/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Current Asset Value calculated?
Net Current Asset Value is calculated from a company's financial statements. For Vivesto AB (OASMY), the current Net Current Asset Value is $0.01 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Vivesto AB is a research and development company that develops new treatment options for patients suffering from difficult-to-treat cancer. The company's product development leverages its proprietary technology platforms to manufacture novel drug formulations that are intended to demonstrate improved properties in comparison with current alternatives, which can lead to a reduced side-effect profile and an expanded therapeutic area. The company has a portfolio of projects targeting cancer treatments.
26GF Score
Get the complete analysis for OASMY
Net Current Asset Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OASMY has been successfully added to your 
